Cynthia A. Behling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cynthia A. Behling has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey B. Schwimmer
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics University of California San Diego School of Medicine La Jolla California USA
2 shared publications - Kimberly P. Newton
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA
2 shared publications - Ajay Jain
Department of Pediatrics, School of Medicine, Saint Louis University, 1402 S. Grand Blvd, St. Louis, MO 63104, USA
1 shared publication Andrew Wang
Division of Gastroenterology, Department of Pediatrics, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA
1 shared publicationBonnie Lin
Division of Gastroenterology, Department of Pediatrics, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA
1 shared publication- Eleanor G. Hansen
Division of Gastroenterology, Department of Pediatrics, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA
1 shared publication
Latest Publications
- Open Access
- 17 October 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (1) , 129-142
Reclassifying pediatric NAFLD using the steatotic liver disease framework: A multicenter retrospective study from the NASH CRN
Background and Aims: The terminology for hepatic steatosis and NAFLD was revised under the umbrella of steatotic liver disease, with metabolic dysfunction–associated steatotic liver disease (MASLD) as the primary subtype. MASLD is defined by hepatic steatosis plus at least 1 cardiometabolic risk factor. A new category, Met-ALD, describes MASLD with alcohol consumption below the defined thresholds for alcohol-associated liver disease (ALD). While adult studies have demonstrated strong concordance between NAFLD and MASLD, the applicability of this framework in children remains unclear. Approach and Results: We assessed children clinically diagnosed with NAFLD and enrolled in the NASH CRN who had available liver histology. Clinical and demographic data, including body mass index, hepatotoxic medication use, and alcohol intake, were analyzed. Liver biopsies were centrally reviewed to confirm hepatic steatosis and evaluate for alternative etiologies. Participants were reclassified using the steatotic liver disease framework. Among 1019 children diagnosed with NAFLD, 858 (84%) met MASLD criteria. The average number of cardiometabolic risk factors per participant was 2.7±1.1; 41 (4.7%) met all five. Thirty-three participants (3.2%) were reclassified as Met-ALD, a prevalence that rose to 5.4% among adolescents. Sixty-six children (6.5%) were reclassified as drug-induced steatotic liver disease. Conclusions: Most children with NAFLD met MASLD criteria, but nearly 1 in 6 were reclassified based on alcohol use or medication exposure. These findings highlight the need for a systematic diagnostic approach accounting for metabolic risk factors, alcohol use, and medication-related liver injury.
- 17 October 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (1) , 129-142
Open AccessReclassifying pediatric NAFLD using the steatotic liver disease framework: A multicenter retrospective study from the NASH CRN
Background and Aims: The terminology for hepatic steatosis and NAFLD was revised under the umbrella of steatotic liver disease, with metabolic dysfunction–associated steatotic liver disease (MASLD) as the primary subtype. MASLD is defined by hepatic steatosis plus at least 1 cardiometabolic risk factor. A new category, Met-ALD, describes MASLD with alcohol consumption below the defined thresholds for alcohol-associated liver disease (ALD). While adult studies have demonstrated strong concordance between NAFLD and MASLD, the applicability of this framework in children remains unclear. Approach and Results: We assessed children clinically diagnosed with NAFLD and enrolled in the NASH CRN who had available liver histology. Clinical and demographic data, including body mass index, hepatotoxic medication use, and alcohol intake, were analyzed. Liver biopsies were centrally reviewed to confirm hepatic steatosis and evaluate for alternative etiologies. Participants were reclassified using the steatotic liver disease framework. Among 1019 children diagnosed with NAFLD, 858 (84%) met MASLD criteria. The average number of cardiometabolic risk factors per participant was 2.7±1.1; 41 (4.7%) met all five. Thirty-three participants (3.2%) were reclassified as Met-ALD, a prevalence that rose to 5.4% among adolescents. Sixty-six children (6.5%) were reclassified as drug-induced steatotic liver disease. Conclusions: Most children with NAFLD met MASLD criteria, but nearly 1 in 6 were reclassified based on alcohol use or medication exposure. These findings highlight the need for a systematic diagnostic approach accounting for metabolic risk factors, alcohol use, and medication-related liver injury.
- Top Cited Papers
- 22 April 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 561-574
Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. Approach & Results: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children’s Hospital San Diego. We included 1,096 children aged 2–18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained via the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower high-density lipoprotein levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3,664 per 100,000 person-years), hypertension (1,901), obstructive sleep apnea (1,185), and type 2 diabetes (911). Conclusions: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD. Export
- 22 April 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 561-574
Top Cited PapersLong-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. Approach & Results: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children’s Hospital San Diego. We included 1,096 children aged 2–18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained via the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower high-density lipoprotein levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3,664 per 100,000 person-years), hypertension (1,901), obstructive sleep apnea (1,185), and type 2 diabetes (911). Conclusions: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD. Export